FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223415175> ?p ?o ?g. }

• W4223415175 endingPage "100862" @default.
• W4223415175 startingPage "100862" @default.
• W4223415175 abstract "We conducted a retrospective tumor tissue analysis as part of the BRIM3 trial to evaluate the theragnostic significance of tumor-infiltrating lymphocytes (TILs) and melanoma cell proliferation. Using manual semi-quantitative analyses, we assessed the density of TILs by pathology review of tissue sections stained with hematoxylin and eosin (H&E TIL score) and by immunohistochemistry (IHC) with an anti-CD8 antibody (CD8 TIL score); also, the melanoma cell proliferation by IHC with an anti-Ki67 antibody. Three hundred and fifty-three, 280, and 172 patients' tumor tissue samples were available for H&E, CD8, and Ki67 IHC analysis, respectively. There was no association between high (2+, 3+) peritumoral and intratumoral H&E and/or TIL CD8 score or high Ki67 proliferation index (>15%) with serum LDH level and stage IV melanoma. Neither high Ki67 proliferation, nor high peritumoral and/or intratumoral TIL score was significantly associated with objective antitumor response in any treatment arm. High intratumoral and high peritumoral CD8 TIL score was significantly associated with progression-free survival (PFS) only in DTIC-treated patients (P = 0.002 and 0.037, respectively); in vemurafenib-treated patients, high intratumoral and/or peritumoral CD8 TIL score was not significant (log-rank P = 0.053 and 0.062, respectively). Nevertheless, a high peritumoral CD8 TIL score was a significant predictor of PFS and overall survival after adjustment for age, sex, serum LDH, ECOG performance status, and treatment arm in a Cox regression model. Vemurafenib does not only benefit patients bearing brisk TILs; even vemurafenib-treated patients with absent and/or non-brisk TILs tend to have longer PFS compared to DTIC-treated patients with brisk TILs. High peritumoral CD8 TIL score is a favorable prognostic factor independent of well-established AJCC staging factors." @default.
• W4223415175 created "2022-04-14" @default.
• W4223415175 creator A5001152248 @default.
• W4223415175 creator A5006412575 @default.
• W4223415175 creator A5027712976 @default.
• W4223415175 creator A5046203056 @default.
• W4223415175 creator A5046386901 @default.
• W4223415175 creator A5050390394 @default.
• W4223415175 creator A5075736993 @default.
• W4223415175 date "2022-06-01" @default.
• W4223415175 modified "2023-09-26" @default.
• W4223415175 title "Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial)" @default.
• W4223415175 cites W1950829641 @default.
• W4223415175 cites W2103675014 @default.
• W4223415175 cites W2111404068 @default.
• W4223415175 cites W2114903025 @default.
• W4223415175 cites W2135708326 @default.
• W4223415175 cites W2142020296 @default.
• W4223415175 cites W2166262263 @default.
• W4223415175 cites W2518470597 @default.
• W4223415175 cites W2553200914 @default.
• W4223415175 cites W2606149937 @default.
• W4223415175 cites W2618481999 @default.
• W4223415175 cites W2761314488 @default.
• W4223415175 cites W2793817570 @default.
• W4223415175 cites W2919111067 @default.
• W4223415175 cites W2948716731 @default.
• W4223415175 cites W2999572558 @default.
• W4223415175 cites W3004219326 @default.
• W4223415175 cites W3015200356 @default.
• W4223415175 cites W3034459487 @default.
• W4223415175 cites W3090257754 @default.
• W4223415175 cites W3112811149 @default.
• W4223415175 cites W3133660227 @default.
• W4223415175 doi "https://doi.org/10.1016/j.currproblcancer.2022.100862" @default.
• W4223415175 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35398635" @default.
• W4223415175 hasPublicationYear "2022" @default.
• W4223415175 type Work @default.
• W4223415175 citedByCount "2" @default.
• W4223415175 countsByYear W42234151752023 @default.
• W4223415175 crossrefType "journal-article" @default.
• W4223415175 hasAuthorship W4223415175A5001152248 @default.
• W4223415175 hasAuthorship W4223415175A5006412575 @default.
• W4223415175 hasAuthorship W4223415175A5027712976 @default.
• W4223415175 hasAuthorship W4223415175A5046203056 @default.
• W4223415175 hasAuthorship W4223415175A5046386901 @default.
• W4223415175 hasAuthorship W4223415175A5050390394 @default.
• W4223415175 hasAuthorship W4223415175A5075736993 @default.
• W4223415175 hasBestOaLocation W42234151751 @default.
• W4223415175 hasConcept C121608353 @default.
• W4223415175 hasConcept C125473707 @default.
• W4223415175 hasConcept C126322002 @default.
• W4223415175 hasConcept C142724271 @default.
• W4223415175 hasConcept C143998085 @default.
• W4223415175 hasConcept C167672396 @default.
• W4223415175 hasConcept C203014093 @default.
• W4223415175 hasConcept C204232928 @default.
• W4223415175 hasConcept C2776131300 @default.
• W4223415175 hasConcept C2777658100 @default.
• W4223415175 hasConcept C2777701055 @default.
• W4223415175 hasConcept C2778326572 @default.
• W4223415175 hasConcept C2994587330 @default.
• W4223415175 hasConcept C502942594 @default.
• W4223415175 hasConcept C71924100 @default.
• W4223415175 hasConcept C8891405 @default.
• W4223415175 hasConceptScore W4223415175C121608353 @default.
• W4223415175 hasConceptScore W4223415175C125473707 @default.
• W4223415175 hasConceptScore W4223415175C126322002 @default.
• W4223415175 hasConceptScore W4223415175C142724271 @default.
• W4223415175 hasConceptScore W4223415175C143998085 @default.
• W4223415175 hasConceptScore W4223415175C167672396 @default.
• W4223415175 hasConceptScore W4223415175C203014093 @default.
• W4223415175 hasConceptScore W4223415175C204232928 @default.
• W4223415175 hasConceptScore W4223415175C2776131300 @default.
• W4223415175 hasConceptScore W4223415175C2777658100 @default.
• W4223415175 hasConceptScore W4223415175C2777701055 @default.
• W4223415175 hasConceptScore W4223415175C2778326572 @default.
• W4223415175 hasConceptScore W4223415175C2994587330 @default.
• W4223415175 hasConceptScore W4223415175C502942594 @default.
• W4223415175 hasConceptScore W4223415175C71924100 @default.
• W4223415175 hasConceptScore W4223415175C8891405 @default.
• W4223415175 hasIssue "3" @default.
• W4223415175 hasLocation W42234151751 @default.
• W4223415175 hasLocation W42234151752 @default.
• W4223415175 hasOpenAccess W4223415175 @default.
• W4223415175 hasPrimaryLocation W42234151751 @default.
• W4223415175 hasRelatedWork W1234495162 @default.
• W4223415175 hasRelatedWork W2011949887 @default.
• W4223415175 hasRelatedWork W2054352305 @default.
• W4223415175 hasRelatedWork W2079153990 @default.
• W4223415175 hasRelatedWork W2375803463 @default.
• W4223415175 hasRelatedWork W2508523250 @default.
• W4223415175 hasRelatedWork W2518421251 @default.
• W4223415175 hasRelatedWork W4241968666 @default.
• W4223415175 hasRelatedWork W4318589268 @default.
• W4223415175 hasRelatedWork W6572435 @default.
• W4223415175 hasVolume "46" @default.
• W4223415175 isParatext "false" @default.

• next